Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.

M. Kamrava; Kwong Y. Tsang; R. A. Madan; A. Kaushal; C. N. Coleman; J. Gulley

doi:10.1155/2009/363914

Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.

M. Kamrava, Kwong Y. Tsang, R. A. Madan, A. Kaushal, C. N. Coleman, J. Gulley

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

We describe a patient with node positive prostate cancer treated with radiation, androgen deprivation, and immunotherapy with long-term overall survival and PSA control. ELISPOT immunoassay studies demonstrated PSA specific T-cells prior to starting vaccine therapy suggesting that this positive response may be related to an improved antitumor immune response of the patient, increased immunogenicity of the tumor, or decreased activation of immune escape pathways. Further evaluation of therapeutic cancer vaccines in combination with radiation and hormonal therapy in the definitive management of prostate cancer is warranted.

Original language	English (US)
Pages (from-to)	363914
Number of pages	1
Journal	Clinical & developmental immunology
Volume	2009
DOIs	https://doi.org/10.1155/2009/363914
State	Published - 2009
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1155/2009/363914

Cite this

@article{842e7168b4694b97a89040d1768d3818,

title = "Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.",

abstract = "We describe a patient with node positive prostate cancer treated with radiation, androgen deprivation, and immunotherapy with long-term overall survival and PSA control. ELISPOT immunoassay studies demonstrated PSA specific T-cells prior to starting vaccine therapy suggesting that this positive response may be related to an improved antitumor immune response of the patient, increased immunogenicity of the tumor, or decreased activation of immune escape pathways. Further evaluation of therapeutic cancer vaccines in combination with radiation and hormonal therapy in the definitive management of prostate cancer is warranted.",

author = "M. Kamrava and Tsang, {Kwong Y.} and Madan, {R. A.} and A. Kaushal and Coleman, {C. N.} and J. Gulley",

year = "2009",

doi = "10.1155/2009/363914",

language = "English (US)",

volume = "2009",

pages = "363914",

journal = "Clinical & developmental immunology",

issn = "2314-8861",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.

AU - Kamrava, M.

AU - Tsang, Kwong Y.

AU - Madan, R. A.

AU - Kaushal, A.

AU - Coleman, C. N.

AU - Gulley, J.

PY - 2009

Y1 - 2009

N2 - We describe a patient with node positive prostate cancer treated with radiation, androgen deprivation, and immunotherapy with long-term overall survival and PSA control. ELISPOT immunoassay studies demonstrated PSA specific T-cells prior to starting vaccine therapy suggesting that this positive response may be related to an improved antitumor immune response of the patient, increased immunogenicity of the tumor, or decreased activation of immune escape pathways. Further evaluation of therapeutic cancer vaccines in combination with radiation and hormonal therapy in the definitive management of prostate cancer is warranted.

AB - We describe a patient with node positive prostate cancer treated with radiation, androgen deprivation, and immunotherapy with long-term overall survival and PSA control. ELISPOT immunoassay studies demonstrated PSA specific T-cells prior to starting vaccine therapy suggesting that this positive response may be related to an improved antitumor immune response of the patient, increased immunogenicity of the tumor, or decreased activation of immune escape pathways. Further evaluation of therapeutic cancer vaccines in combination with radiation and hormonal therapy in the definitive management of prostate cancer is warranted.

UR - http://www.scopus.com/inward/record.url?scp=77953411181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953411181&partnerID=8YFLogxK

U2 - 10.1155/2009/363914

DO - 10.1155/2009/363914

M3 - Article

C2 - 20224813

AN - SCOPUS:77953411181

SN - 2314-8861

VL - 2009

SP - 363914

JO - Clinical & developmental immunology

JF - Clinical & developmental immunology

ER -

Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this